News

Pancreatic Cancer causes 40,000 deaths each year, with available chemotherapy regimens providing only an average of 6-11 months survival. WashU-born company Accuronix, founded by Dr. William Hawkins and Robert Mach, PhD. (now of the University of Pennsylvania), is taking on this difficult disease by developing novel therapies to selectively target cancer cells, increasing effectiveness and decreasing toxicity.

President and CEO of Accuronix, Dennis Schafer brings more than 30 years experience as a serial Biotech entrepreneur, participating in 12 startups throughout his career.

Read More

BioGenerator and the state-funded Missouri Technology Corp. have invested in a cancer-drug startup that’s based on Washington University research.

The startup, Accuronix Therapeutics, raised a total of $625,000, with BioGenerator as the lead investor. Accuronix is developing drugs for difficult-to-treat forms of cancer, starting with pancreatic cancer.

Read more

Company developing pharmaceuticals to treat the most difficult cancers

BioGenerator, an evergreen investor that creates, grows and invests in promising companies and entrepreneurs, has led a $625,000 investment round in Accuronix Therapeutics, a biotech company developing breakthrough treatments for the most difficult types of cancer.

Accuronix was established based on technologies developed at Washington University in St. Louis by Dr. William Hawkins, Professor of Surgery, and his collaborator, Dr. Robert Mach, Professor of Radiology at University of Pennsylvania. With a particular focus in pancreatic cancer, the company’s mission is to develop novel oncology therapies founded on technology that selectively targets overexpressed receptors on cancer cells.

Read More